Stiripentol for Dravet Syndrome: Is it Worth It?

E. Kossoff

DOI: https://doi.org/10.5698/1535-7597-14.1.22

2014-01-01

Epilepsy Currents

Abstract:Commentary Dravet syndrome is tough. Children with this incurable genetic condition typically face a life dealing with developmental disability, motor impairment, and often intractable epilepsy (1). Antiepileptic drugs (AEDs) are only partially effective, and treatments such as ketogenic diets and vagus nerve stimulation are frequently tried to improve quality of life (2, 3). As is often the case, parents will look for any answer, no matter the cost, to try to help their children. Stiripentol is an allosteric modulator of the GABA-A receptor, first demonstrated as effective in animal models in the late 1970s and then tried in humans in the early 1980s (4). As often happens, initial trials in partial epilepsy ensued, but in 2000, it was first reported by Chiron and colleagues as helpful for Dravet syndrome (5). Further studies followed, with continued efficacy demonstrated (6). Stiripentol, however, also is a potent cytochrome P450 inhibitor, which decreases the metabolism— hence raising the level of drugs such as clobazam (7). Early trials revealed possible synergistic benefits when stiripentol was combined with clobazam and valproate, raising a question regarding whether stiripentol’s efficacy was primarily related to increased clobazam levels (5). At this time, stiripentol is available only in Europe, Canada, and Japan, so families in the United States have to pay cash for it to be shipped to their household from abroad. This cost can be as high as $1,000 for a month supply via Caligor in New York City or 1,500 euros per month from Europe directly (Dravet Syndrome Foundation, personal communication). For a family struggling with a devastating disease with comorbidities and a child already receiving (and paying) for multiple other AEDs, the cost-effectiveness of stiripentol is a reasonable concern (8). In 2004, this was addressed by the group at Alberta Children’s Hospital, and stiripentol was deemed worth the cost; however, that was when it was priced at mean $135 per month (9). The present study was designed to further investigate the value of stiripentol for children with Dravet syndrome, querying child neurologists who obtained this drug for their U.S. patients over a 7-year period. In total, 82 children were identified, most with very severe epilepsy. A median of 7 AEDs were tried, half had been on dietary therapy, and one-quarter Stiripentol in Dravet Syndrome: Results of a Retrospective U.S. Study.